Literature DB >> 12019116

Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime.

Sergei B Vakulenko1, Dasantila Golemi, Bruce Geryk, Maxim Suvorov, James R Knox, Shahriar Mobashery, Stephen A Lerner.   

Abstract

The class C beta-lactamase from Enterobacter cloacae P99 confers resistance to a wide range of broad-spectrum beta-lactams but not to the newer cephalosporin cefepime. Using PCR mutagenesis of the E. cloacae P99 ampC gene, we obtained a Leu-293-Pro mutant of the P99 beta-lactamase conferring a higher MIC of cefepime (MIC, 8 microg/ml, compared with 0.5 microg/ml conferred by the wild-type enzyme). In addition, the mutant enzyme produced higher resistance to ceftazidime but not to the other beta-lactams tested. Mutants with 15 other replacements of Leu-293 were prepared by site-directed random mutagenesis. None of these mutant enzymes conferred MICs of cefepime higher than that conferred by Leu-293-Pro. We determined the kinetic parameters of the purified E. cloacae P99 beta-lactamase and the Leu-293-Pro mutant enzyme. The catalytic efficiencies (k(cat)/K(m)) of the Leu-293-Pro mutant beta-lactamase for cefepime and ceftazidime were increased relative to the respective catalytic efficiencies of the wild-type P99 beta-lactamase. These differences likely contribute to the higher MICs of cefepime and ceftazidime conferred by this mutant beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019116      PMCID: PMC127218          DOI: 10.1128/AAC.46.6.1966-1970.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia.

Authors:  A Bauernfeind; I Schneider; R Jungwirth; H Sahly; U Ullmann
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention.

Authors:  K Bush; S Mobashery
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

Review 3.  Plasmid-encoded AmpC beta-lactamases: how far have we gone 10 years after the discovery?

Authors:  A Bauernfeind; Y Chong; K Lee
Journal:  Yonsei Med J       Date:  1998-12       Impact factor: 2.759

4.  Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles.

Authors:  L Martínez-Martínez; M C Conejo; A Pascual; S Hernández-Allés; S Ballesta; E Ramírez De Arellano-Ramos; V J Benedí; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  An extended-spectrum AmpC-type beta-lactamase obtained by in vitro antibiotic selection.

Authors:  M I Morosini; M C Negri; B Shoichet; M R Baquero; F Baquero; J Blázquez
Journal:  FEMS Microbiol Lett       Date:  1998-08-01       Impact factor: 2.742

6.  When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with beta-lactams.

Authors:  B Lakaye; A Dubus; S Lepage; S Groslambert; J M Frère
Journal:  Mol Microbiol       Date:  1999-01       Impact factor: 3.501

7.  Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae.

Authors:  L Martínez-Martínez; A Pascual; S Hernández-Allés; D Alvarez-Díaz; A I Suárez; J Tran; V J Benedí; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  Salmonella enteritidis: AmpC plasmid-mediated inducible beta-lactamase (DHA-1) with an ampR gene from Morganella morganii.

Authors:  G Barnaud; G Arlet; C Verdet; O Gaillot; P H Lagrange; A Philippon
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

9.  Characterization and nucleotide sequence of a Klebsiella oxytoca cryptic plasmid encoding a CMY-type beta-lactamase: confirmation that the plasmid-mediated cephamycinase originated from the Citrobacter freundii AmpC beta-lactamase.

Authors:  S W Wu; K Dornbusch; G Kronvall; M Norgren
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

10.  Transferable class C beta-lactamases in Escherichia coli strains isolated in Greek hospitals and characterization of two enzyme variants (LAT-3 and LAT-4) closely related to Citrobacter freundii AmpC beta-lactamase.

Authors:  M Gazouli; L S Tzouvelekis; A C Vatopoulos; E Tzelepi
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790

View more
  18 in total

1.  Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC beta-lactamase.

Authors:  Miriam Barlow; Barry G Hall
Journal:  Genetics       Date:  2003-05       Impact factor: 4.562

2.  Identification of residues critical for catalysis in a class C beta-lactamase by combinatorial scanning mutagenesis.

Authors:  Shalom D Goldberg; William Iannuccilli; Tuan Nguyen; Jingyue Ju; Virginia W Cornish
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

3.  In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.

Authors:  João Pires; Magdalena Taracila; Christopher R Bethel; Yohei Doi; Sara Kasraian; Regula Tinguely; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution.

Authors:  Yu Chen; George Minasov; Tomer A Roth; Fabio Prati; Brian K Shoichet
Journal:  J Am Chem Soc       Date:  2006-03-08       Impact factor: 15.419

5.  Hydrolysis spectrum extension of CMY-2-like β-lactamases resulting from structural alteration in the Y-X-N loop.

Authors:  Sandrine Dahyot; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

Review 6.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

7.  Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?

Authors:  Markus Hilty; Parham Sendi; Salome N Seiffert; Sara Droz; Vincent Perreten; Andrea M Hujer; Robert A Bonomo; Kathrin Mühlemann; Andrea Endimiani
Journal:  Int J Antimicrob Agents       Date:  2013-01-10       Impact factor: 5.283

8.  Structure of AmpC beta-lactamase (AmpCD) from an Escherichia coli clinical isolate with a tripeptide deletion (Gly286-Ser287-Asp288) in the H10 helix.

Authors:  Yoshihiro Yamaguchi; Genta Sato; Yuriko Yamagata; Yohei Doi; Jun-ichi Wachino; Yoshichika Arakawa; Koki Matsuda; Hiromasa Kurosaki
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-05-22

9.  Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.

Authors:  Que-Tien Tran; Myrielle Dupont; Jean-Philippe Lavigne; Jacqueline Chevalier; Jean-Marie Pagès; Albert Sotto; Anne Davin-Regli
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

10.  HotSpot Wizard: a web server for identification of hot spots in protein engineering.

Authors:  Antonin Pavelka; Eva Chovancova; Jiri Damborsky
Journal:  Nucleic Acids Res       Date:  2009-05-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.